Spinout Active LTD

Company profile

Microbiosensor Limited

Home - microbiosensor - microbiosensor

Welcome to MicroBioSensor

CRN
08332089
Founded
2012
Age
13

Overview

Browse spinouts
Legal name
MICROBIOSENSOR LIMITED
Region
North West England
Registered address
SUITE C VICTORIA HOUSE
19-21 ACK LANE EAST
BRAMHALL
CHESHIRE
SK7 2BE
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

11 levels 4 ultimate controllers
1
Company Active LTD
Microbiosensor Limited
CRN 08332089
2
Direct controller Active LTD
3
Direct controller Active LTD
UK FF Nominees Limited
CRN 12591650
4
Direct controller Active LLP
5
Intermediate controller Active LTD
6
Intermediate controller Active LTD
7
Intermediate controller Active LTD
UK FF Topco Limited
CRN 12590448
8
Intermediate controller Active LLP
9
Intermediate controller Active LTD
10
Intermediate controller Active PLC
Mattioli Woods PLC
CRN 03140521
11
Ultimate controller Active LTD
12
Intermediate controller Active LTD
13
Intermediate controller Active LTD
14
Intermediate controller Active LTD
15
Intermediate controller Active LLP
Barnett Waddingham LLP
CRN OC307678
16
Intermediate controller Active LTD
17
Intermediate controller Active LTD
18
Ultimate controller
CMP70165
CRN CMP70165
19
Intermediate controller Active LTD
20
Ultimate controller Active LTD
21
Intermediate controller Active LTD
22
Intermediate controller Active LTD
HGH Midco 3 Limited
CRN 13646017
23
Intermediate controller Active LTD
Hig Finance 2 Limited
CRN 10842605
24
Intermediate controller Active LTD
HGH Finance Limited
CRN 13645436
25
Intermediate controller Active LTD
HGH Midco 2 Limited
CRN 13644440
26
Intermediate controller Active LTD
HGH Midco 1 Limited
CRN 13642978
27
Ultimate controller Active LTD

Company events

Reference milestones and recent Companies House filing stream events.

6 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

28 Dec
2025

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

14 Dec
2024

Confirmation statement filed

Confirmation

Last confirmation statement made up date

07 Oct
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzNzk4MTgyOGFkaXF6a2N4 | Paper/PDF filed

Published 08 Oct 2024 06:16

14 Dec
2012

Incorporated

Inception

Company registered at Companies House

Spinout profile

3 entries

Company description

Microbiosensor is a medical device company developing disposable point-of-care safety monitors for detecting microbial infection. Microbiological monitoring is especially important for long-term users of medical devices. Medical device use is one of the highest risk factors for nosocomial infection, affecting nearly 2 million patients and killing approximately 90,000 annually in the US alone. At risk groups include patients with chronic wounds, such as diabetic leg ulcers, or those requiring long-term invasive medical device intervention, such as kidney dialysis patients. Microbiosensor Ltd is addressing this need for improved infection monitoring head-on, by offering the market unique, robust and inexpensive diagnostic solutions. Our devices provide continuous safety monitoring, enhancing patient care by allowing earlier intervention than is currently possible. This will improve treatment outcomes and ultimately help in the fight against multi-drug resistance, by improving the management of the remaining arsenal of effective antibiotic drugs.

MicroBioSensor develops medical devices that create signals when an infection begins to escalate, aiming to facilitate prompt intervention.

Project impact

Microbiosensor has secured around £4m funding to develop its technology. The company's first product is expected to be CE marked in 2018, and should save each EU healthcare provider around £10m pa.

Microbiosensor Ltd
2013
MicroBioSensor
2012
MicroBioSensor
2012

Public funding

4 awards
First funded
2017
Funded years
2017, 2019, 2020
Age at first award
4 years

Projects

2020 Collaborative R&D Lead participant

From niche 'in clinic' diagnostic to high-volume home-use medical product

9 Jul 2020 to 9 Jul 2023

Awarded
£999,903
Total cost £999,903

From niche 'in clinic' diagnostic to high-volume home-use medical product

2020 Study Lead participant

PeriFAST: a new product to rapidly identify effective antibiotics to treat peritonitis in vulnerable kidney and liver failure patients.

1 Jun 2020 to 31 May 2022

Awarded
£822,878
Total cost £1,175,540

Patients with advanced kidney disease, who are reliant on peritoneal dialysis (PD), and advanced liver disease patients, with liver cirrhosis, are both at risk of life-threatening infection in the abdomen, referred to as 'peritonitis'. This develops quickly, and typically requires hospital admission. The choice of antibiotic therapy has to be made by doct...

2019 Collaborative R&D Lead participant

Same-day Test for Antibiotic Resistance (STAR)

1 May 2019 to 31 Jan 2022

Awarded
£621,475
Total cost £1,242,950

"The misdiagnosis and incorrect treatment of Urinary Tract Infections (UTIs) is a significant global healthcare problem and a contributory factor to growing antibiotic resistance levels. UTIs are the most common non-intestinal infection in women worldwide (over 15-million new infections p.a.). In the UK they are the 3rd most common reason for emergency ad...

2017 Collaborative R&D Lead participant

Evaluation, Prototyping and Production Pathway of a Diagnostic for Peritoneal Dialysis Infection

1 Feb 2017 to 31 Jan 2019

Awarded
£688,316
Total cost £983,308

Increasing numbers of people are suffering from kidney failure, particularly resulting from diabetes. Patients with kidney failure can have two types of dialysis; Peritoneal- or Haemo-dialysis. Peritoneal dialysis can be done at home and gives the patient the most freedom and flexibility, it is also cheaper than haemodialysis. However, it carries a risk o...

Product types

Collaborative R&D Study